In the last trading session, 2.05 million shares of the Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) were traded, and its beta was 0.29. Most recently the company’s share price was $1.50, and it changed around $0.01 or 0.67% from the last close, which brings the market valuation of the company to $240.04M. IRWD currently trades at a discount to its 52-week high of $9.01, offering almost -500.67% off that amount. The share price’s 52-week low was $1.34, which indicates that the current value has risen by an impressive 10.67% since then. We note from Ironwood Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 3.53 million shares, with the 3-month average coming to 3.29 million.
Ironwood Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended IRWD as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Ironwood Pharmaceuticals Inc is expected to report earnings per share of -0.01 for the current quarter.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) trade information
Instantly IRWD has showed a green trend with a performance of 0.67% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.5500 on recent trading dayincreased the stock’s daily price by 3.23%. The company’s shares are currently down -66.14% year-to-date, but still up 3.45% over the last five days. On the other hand, Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is -16.67% down in the 30-day period. We can see from the shorts that 12.05 million shares have been sold at a short interest cover period of 2.59 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 78.57% from its current value. Analyst projections state that IRWD is forecast to be at a low of $7 and a high of $7.
Ironwood Pharmaceuticals Inc (IRWD) estimates and forecasts
The year-over-year growth rate is expected to be -18.31%, down from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 67.02M in revenue for the current quarter. 5 analysts expect Ironwood Pharmaceuticals Inc to make 73.08M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 74.88M and 94.4M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -10.49%. Forecasts for the next quarter put sales growth at -22.58%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -40.82%.
IRWD Dividends
Ironwood Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.95% of Ironwood Pharmaceuticals Inc shares, and 104.54% of them are in the hands of institutional investors. The stock currently has a share float of 106.63%. Ironwood Pharmaceuticals Inc stock is held by 306.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 14.3868% of the shares, which is about 22.88 million shares worth $149.16 million.
VANGUARD GROUP INC, with 13.6737% or 21.56 million shares worth $140.59 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Pacer US Small Cap Cash Cows 100 ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Oct 31, 2024 . The former held 11.05 shares worth $16.57 million, making up 6.90% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 4.19 shares worth around $6.29 million, which represents about 2.62% of the total shares outstanding.
